Sol-Gel Technologies Ltd. logo
Sol-Gel Technologies Ltd. SLGL
$ 84.69 0.77%
report update icon

Quarterly report 2025-Q4
added 05-28-2026

Sol-Gel Technologies Ltd. Income Statement 2025-2011 | SLGL

Brief overview of income trends at Sol-Gel Technologies Ltd.

The conclusions below are based on five years of reported results. Revenue at Sol-Gel Technologies Ltd. moved from $8.8 million in 2020 to $19.4 million in 2025. Overall revenue changed by +121%, equal to an annualized rate of about 17.2%. Top-line growth remained consistently strong over the period.

EBITDA was −$29.3 million at the beginning and −$7.4 million at the end of the period (+74.6%). The operating result developed less favorably than sales. EBITDA margin was −333.9% at the start and −38.3% at the end. Higher profitability strengthens the quality of operating growth.

Comparing the endpoints shows a move from −$29.3 million to −$6.1 million. The negative result improved without reaching break-even.

The market value of the business moved from 220 million dollars to 203 million dollars, or −7.5%. Capitalization grew more slowly than the underlying results.

What the figures show

The figures do not all move in the same direction. The financial profile benefits from a stronger final result, higher operating efficiency and a larger revenue base. The weaker side of the profile includes a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Sol-Gel Technologies Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

203 M 1.31 M 2.65 M 63.6 M 161 M 220 M 251 M 107 M 17.3 M - - - - - -

Shares

2.79 M 2.79 M 2.71 M 23.1 M 23.1 M 22.6 M 19.5 M 17.9 M 6.29 M - - - - - -

Historical Prices

73 0.47 0.98 2.75 6.97 9.73 12.8 5.99 - - - - - - -

Net Income

-6.13 M -10.6 M -27.2 M -14.9 M 3.22 M -29.3 M -24.6 M -32.2 M -31.6 M -20.8 M -9.66 M - - - -

Revenue

19.4 M 11.5 M 1.55 M 3.88 M 31.3 M 8.77 M 22.9 M 129 K 174 K - - - - - -

Operating Income

-7.54 M -12 M -29.3 M -16.2 M 2.96 M -30.2 M -26 M -33.5 M -31.6 M -20.8 M -9.65 M - - - -

EBITDA

-7.43 M -11.8 M -29 M -15.7 M 3.84 M -29.3 M -25.1 M -32.8 M -31.2 M -20.4 M -9.35 M - - - -

Operating Expenses

- - - - - - 48.9 M 33.6 M 31.8 M - - - - - -

General and Administrative Expenses

4.18 M 5.75 M 7.37 M 7.44 M 8.45 M 11.1 M 8.28 M 5.5 M 6 M 3.73 M 2.46 M - - - -

All numbers in USD currency

Quarterly Income Statement Sol-Gel Technologies Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.79 M 2.79 M 2.79 M 27.9 M 2.71 M 27.7 M - - - - 23.1 M - 23 M - 23 M - 22.9 M - 20.4 M - 18.9 M - 18.9 M - 18.9 M - 6.29 M - - - 6.29 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-6.13 M 11.6 M -10.6 M 1.98 M -27.2 M -5.97 M - - - - - - -8.03 M - - - -7.07 M - - - -4.93 M - - - -6.91 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

19.4 M 17.3 M 11.5 M 5.43 M 1.55 M 594 K - - - - - - 928 K - - - 1.13 M - - - 7.79 M - - - 49 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-7.54 M 11.2 M -12 M 1.62 M -29.3 M -6.53 M - - - - - - -8.04 M - - - -7.55 M - - - -5.28 M - - - -7.29 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-7.43 M 11.3 M -11.8 M 1.75 M -29 M -6.34 M - - - - - - -8.04 M - - - -7.55 M - - - -5.28 M - - - -7.29 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.18 M 1.38 M 5.75 M 1.37 M 7.37 M 1.81 M - - - - - - 2.04 M - - - 2.23 M - - - 1.64 M - - - 1.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Sol-Gel Technologies Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada